Shots:
The NMPA has approved the IND application to initiate the P-I study of EVER001 (BTK inhibitor) in patients with glomerular diseases. The study evaluates the safety, efficacy, PK, and PD of EVER001
Under a 2021 exclusive license agreement with Sinovent and SinoMab BioScience, Everest holds the global rights to develop, produce and commercialize EVER001 for renal diseases
The P-I study results showed that the therapy exhibited high selectivity, excellent PK properties, a safety profile, and robust target engagement. The company highlights a long-term growth strategy to advance high-quality treatments for the benefit of patients with unmet demand globally
Ref: PRNewswire | Image: Everest Medicines
